📊 UTHR Key Takeaways
Is UNITED THERAPEUTICS Corp (UTHR) a Good Investment?
United Therapeutics demonstrates exceptional fundamental strength with 87.9% gross margins, 41.9% net margins, and a fortress balance sheet carrying zero debt and $1.6B in cash. Revenue and earnings growth are solid at 10.6% and 11.7% YoY respectively, while generating robust $1.0B annual free cash flow with healthy 32.7% FCF margin.
Why Buy UNITED THERAPEUTICS Corp Stock? UTHR Key Strengths
- Exceptional profitability with 87.9% gross margin, 46.9% operating margin, and 41.9% net margin
- Fortress balance sheet with zero long-term debt, $1.6B cash reserves, and 6.60x current ratio
- Accelerating earnings growth with EPS up 13.1% YoY and net income up 11.7% YoY
- Strong cash generation with $1.0B free cash flow and 32.7% FCF margin
- High returns on equity (18.8%) and assets (16.9%) demonstrate efficient capital deployment
UTHR Stock Risks: UNITED THERAPEUTICS Corp Investment Risks
- Pharmaceutical industry regulatory risks, patent expirations, and R&D uncertainties
- Elevated insider trading activity (71 Form 4 filings in 90 days) warrants monitoring for insider confidence signals or compensation adjustments
- Industry concentration and cyclical nature exposes portfolio to sector-wide downturns
Key Metrics to Watch
- Revenue growth sustainability and product pipeline advancement
- Gross and operating margin maintenance under competitive pressures
- Free cash flow generation consistency and capital allocation strategy
UNITED THERAPEUTICS Corp (UTHR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.60x current ratio provides a solid financial cushion.
UTHR Profit Margin, ROE & Profitability Analysis
UTHR vs Healthcare Sector: How UNITED THERAPEUTICS Corp Compares
How UNITED THERAPEUTICS Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is UNITED THERAPEUTICS Corp Stock Overvalued? UTHR Valuation Analysis 2026
Based on fundamental analysis, UNITED THERAPEUTICS Corp appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
UNITED THERAPEUTICS Corp Balance Sheet: UTHR Debt, Cash & Liquidity
UTHR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: UNITED THERAPEUTICS Corp's revenue has grown significantly by 89% over the 5-year period, indicating strong business expansion. The most recent EPS of $19.81 reflects profitable operations.
UTHR Revenue Growth, EPS Growth & YoY Performance
UTHR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $748.9M | $309.1M | $6.39 |
| Q2 2025 | $714.9M | $278.1M | $5.85 |
| Q1 2025 | $677.7M | $306.6M | $6.17 |
| Q3 2024 | $609.4M | $267.6M | $5.38 |
| Q2 2024 | $596.5M | $259.2M | $5.24 |
| Q1 2024 | $506.9M | $240.9M | $4.86 |
| Q3 2023 | $516.0M | $239.3M | $4.91 |
| Q2 2023 | $466.9M | $116.0M | $2.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
UNITED THERAPEUTICS Corp Dividends, Buybacks & Capital Allocation
UTHR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for UNITED THERAPEUTICS Corp (CIK: 0001082554)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UTHR
What is the AI rating for UTHR?
UNITED THERAPEUTICS Corp (UTHR) has an AI rating of STRONG BUY with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UTHR's key strengths?
Claude: Exceptional profitability with 87.9% gross margin, 46.9% operating margin, and 41.9% net margin. Fortress balance sheet with zero long-term debt, $1.6B cash reserves, and 6.60x current ratio.
What are the risks of investing in UTHR?
Claude: Pharmaceutical industry regulatory risks, patent expirations, and R&D uncertainties. Elevated insider trading activity (71 Form 4 filings in 90 days) warrants monitoring for insider confidence signals or compensation adjustments.
What is UTHR's revenue and growth?
UNITED THERAPEUTICS Corp reported revenue of $3.2B.
Does UTHR pay dividends?
UNITED THERAPEUTICS Corp does not currently pay dividends.
Where can I find UTHR SEC filings?
Official SEC filings for UNITED THERAPEUTICS Corp (CIK: 0001082554) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UTHR's EPS?
UNITED THERAPEUTICS Corp has a diluted EPS of $27.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UTHR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, UNITED THERAPEUTICS Corp has a STRONG BUY rating with 87% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is UTHR stock overvalued or undervalued?
Valuation metrics for UTHR: ROE of 18.8% (sector avg: 15%), net margin of 41.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy UTHR stock in 2026?
Our dual AI analysis gives UNITED THERAPEUTICS Corp a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is UTHR's free cash flow?
UNITED THERAPEUTICS Corp's operating cash flow is $1.6B, with capital expenditures of $520.5M. FCF margin is 32.7%.
How does UTHR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 41.9% (avg: 12%), ROE 18.8% (avg: 15%), current ratio 6.60 (avg: 2).